Perth, Nov 23, 2015 - (ABN Newswire) - MMJ PhytoTech Ltd (ASX:MMJ) are pleased to provide an Investor Presentation titled, ‘Farm to Pharma: Maximizing Value Along the Chain’.
To view the presentation, please visit: http://media.abnnewswire.net/media/en/docs/ASX-MMJ-743372.pdf
About: MMJ PhytoTech Ltd
MMJ PhytoTech Limited (ASX:MMJ) (formerly PhytoTech Medical Limited) is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.
It’s United Greeneries subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. Satipharm has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.
Through its PhytoTech Therapeutics subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.
